RELATED CONTENT
Piramal Imaging announced the presentation of additional analyses from its florbetaben phase 3 histopathology study, in which the florbetaben positron emission tomography (PET) signal from binding to morphologically distinct beta-amyloid plaques was examined. The analyses also examined the potential influence of plaques in the reference region for quantification. The results, which were presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Baltimore, provide additional details on the topographic distribution of different beta-amyloid aggregates in the brain and on quantification.
June 09, 2015 
Piramal Imaging announced that WVU Healthcare in West Virginia, is the first center in the United States to perform commercial scans using Neuraceq.
August 14, 2014 May 12, 2014 — AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd., have entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune’s Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer’s disease (AD) and potential Tau-related disorders.
May 12, 2014 
The U.S. Food and Drug Administration (FDA) has approved a third beta-amyloid plaque positron emission tomography (PET) imaging radiotracer to identify Alzheimer’s disease. The FDA’s approval of Piramal Imaging’s Neuraceq (florbetaben F-18 injection) comes four weeks after receiving marketing authorization in Europe.
March 20, 2014